1
项与 CART-138(Chinese PLA General Hospital) 相关的临床试验 / Unknown status临床1/2期IIT Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD138 positive multiple myeloma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.
100 项与 CART-138(Chinese PLA General Hospital) 相关的临床结果
100 项与 CART-138(Chinese PLA General Hospital) 相关的转化医学
100 项与 CART-138(Chinese PLA General Hospital) 相关的专利(医药)
100 项与 CART-138(Chinese PLA General Hospital) 相关的药物交易